4.5 Review Book Chapter

alpha 7-Nicotinic Acetylcholine Receptor Agonists for Cognitive Enhancement in Schizophrenia

期刊

ANNUAL REVIEW OF MEDICINE, VOL 65
卷 65, 期 -, 页码 245-261

出版社

ANNUAL REVIEWS
DOI: 10.1146/annurev-med-092112-142937

关键词

chromosome human pair 15; CHRNA7; smoking; autism; clozapine; olanzapine

向作者/读者索取更多资源

alpha 7-Nicotinic acetylcholine receptors have emerged as a potential therapeutic target for the treatment of neurocognitive dysfunctions in schizophrenia that are often resistant to existing antipsychotic drugs. Molecular evidence for involvement in schizophrenia of CHRNA7, the gene for the receptor subunit, in the neurobiology of deficits in attention is a critical rationale for the clinical study of alpha 7-nicotinic receptor agonists to improve neurocognition. Initial clinical trials show enhancement of inhibitory neuron function related to sensory gating and increased attention and working memory, as well as improvement in negative symptoms such as anhedonia and alogia. Further development of this therapeutic strategy requires assessment of interactions with patients' heavy cigarette smoking and the relationship of this mechanism to the therapeutic effects of clozapine and olanzapine, both highly effective therapeutics with significant side effects.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据